Merck Covid Vaccine
- All
- News
- Videos
-
105 Nations To Get Cheaper Merck Covid Pill
- Thursday January 20, 2022
- World News | Agence France-Presse
Generic drug manufacturers will make a more affordable version of Merck's anti-Covid pill for 105 of the world's poorer nations, a UN-backed organisation said on Thursday.
- www.ndtv.com
-
India Clears 2 New Vaccines And Merck's Covid Pill: 10 Points
- Tuesday December 28, 2021
- India News | Edited by Debanish Achom
The centre cleared two more vaccines today and one anti-viral drug to boost the fight against the COVID-19 pandemic. The two latest vaccines cleared by India are Corbevax and Covovax. The anti-viral drug Molnupiravir can be used during emergency.
- www.ndtv.com
-
WHO Aims To Help Poorer Countries Access Vaccine With $10 Covid Pills
- Tuesday October 19, 2021
- World News | Reuters
A World Health Organization-led programme to ensure poorer countries get fair access to COVID-19 vaccines, tests and treatments aim to secure antiviral drugs for patients with mild symptoms for as little as $10 per course.
- www.ndtv.com
-
Merck COVID-19 Pill Has Vital Indian Link, Maker Sees Stock Price Jump
- Tuesday October 12, 2021
- India News | Reuters
India's Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.
- www.ndtv.com
-
Australia To Buy Merck's COVID-19 Pill As Cases Hit Record In Major Cities
- Tuesday October 5, 2021
- World News | Reuters
Australia will buy 300,000 courses of Merck & Co's experimental antiviral pill, Prime Minister Scott Morrison said on Tuesday, as Victoria logged the highest number of daily COVID-19 infections of any state in the country since the pandemic began.
- www.ndtv.com
-
Why Merck's Covid Pill Is Seen As Such A Breakthrough
- Monday October 4, 2021
- World News | James Paton, Bloomberg
As Merck & Co. races ahead with an experimental pill that could play a pivotal role in the fight against Covid-19, efforts are intensifying to bring the drug to developing countries that have struggled to vaccinate their populations.
- www.ndtv.com
-
US Giant Merck Ends Covid Vaccine After Poor Response
- Monday January 25, 2021
- World News | Riley Griffin, Bloomberg
Merck & Co. is discontinuing development of its two experimental Covid-19 vaccines after early trial data showed they failed to generate immune responses comparable to a natural infection or existing vaccines.
- www.ndtv.com
-
Latest News Live Updates: Delhi Moving Towards Herd Immunity From Covid, Indicates Sero-Survey
- Monday January 25, 2021
- India News | Edited by Arun Nair, Deepika Pundir
Delhi is moving towards herd immunity from coronavirus, with 50 to 60 per cent of people in one district having developed antibodies to the virus, the latest round of sero-survey has found, sources said. Herd immunity is what the authorities are trying to achieve with the vaccination programme, in which a critical mass of immune people can stop the...
- www.ndtv.com
-
105 Nations To Get Cheaper Merck Covid Pill
- Thursday January 20, 2022
- World News | Agence France-Presse
Generic drug manufacturers will make a more affordable version of Merck's anti-Covid pill for 105 of the world's poorer nations, a UN-backed organisation said on Thursday.
- www.ndtv.com
-
India Clears 2 New Vaccines And Merck's Covid Pill: 10 Points
- Tuesday December 28, 2021
- India News | Edited by Debanish Achom
The centre cleared two more vaccines today and one anti-viral drug to boost the fight against the COVID-19 pandemic. The two latest vaccines cleared by India are Corbevax and Covovax. The anti-viral drug Molnupiravir can be used during emergency.
- www.ndtv.com
-
WHO Aims To Help Poorer Countries Access Vaccine With $10 Covid Pills
- Tuesday October 19, 2021
- World News | Reuters
A World Health Organization-led programme to ensure poorer countries get fair access to COVID-19 vaccines, tests and treatments aim to secure antiviral drugs for patients with mild symptoms for as little as $10 per course.
- www.ndtv.com
-
Merck COVID-19 Pill Has Vital Indian Link, Maker Sees Stock Price Jump
- Tuesday October 12, 2021
- India News | Reuters
India's Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.
- www.ndtv.com
-
Australia To Buy Merck's COVID-19 Pill As Cases Hit Record In Major Cities
- Tuesday October 5, 2021
- World News | Reuters
Australia will buy 300,000 courses of Merck & Co's experimental antiviral pill, Prime Minister Scott Morrison said on Tuesday, as Victoria logged the highest number of daily COVID-19 infections of any state in the country since the pandemic began.
- www.ndtv.com
-
Why Merck's Covid Pill Is Seen As Such A Breakthrough
- Monday October 4, 2021
- World News | James Paton, Bloomberg
As Merck & Co. races ahead with an experimental pill that could play a pivotal role in the fight against Covid-19, efforts are intensifying to bring the drug to developing countries that have struggled to vaccinate their populations.
- www.ndtv.com
-
US Giant Merck Ends Covid Vaccine After Poor Response
- Monday January 25, 2021
- World News | Riley Griffin, Bloomberg
Merck & Co. is discontinuing development of its two experimental Covid-19 vaccines after early trial data showed they failed to generate immune responses comparable to a natural infection or existing vaccines.
- www.ndtv.com
-
Latest News Live Updates: Delhi Moving Towards Herd Immunity From Covid, Indicates Sero-Survey
- Monday January 25, 2021
- India News | Edited by Arun Nair, Deepika Pundir
Delhi is moving towards herd immunity from coronavirus, with 50 to 60 per cent of people in one district having developed antibodies to the virus, the latest round of sero-survey has found, sources said. Herd immunity is what the authorities are trying to achieve with the vaccination programme, in which a critical mass of immune people can stop the...
- www.ndtv.com